Faculty of Engineering, LTH

Denna sida på svenska This page in English

CREATE Health - A Strategic Centre for Translational Cancer Research

CREATE Health is a Strategic Centre for Translational Cancer research mainly located at Medicon Village in Lund. The Centre is funded mainly by the Swedish Foundation for Strategic Research, Knut and Alice Wallenberg Foundation and VINNOVA. By integrating clinicians and researchers from Lund University Hospital with researchers from the Faculties of Medicine, Natural Sciences and Engineering using a superbly equipped and integrated “omics” platform, concentrated in a single area, a centre unique in its kind has been created.


The vision of CREATE Health is to use an integrative approach to develop novel diagnostics and therapeutics, based on identified markers and molecular signatures and to create a substantial social impact for the patient, through direct application of research for selection of an optimal, individually-based, cancer treatment.

Some of our most important achievements 

  • Discovered new genomic breast tumor subtypes on whole-genome patterns of DNA aberrations 
  • Discovered specific DNA methylation patterns in different subtypes of breast cancer
  • Discovered a prognostic gene expression signature from sub-classification of HER2 amplified/expressing breast cancers
  • Identified protein signatures that define five main types of breast cancer
  • Identified serum biomarker signatures that allow risk classification of breast cancer patients regarding tumor recurrence
  • Identified an association between the expression of EPO receptor and Tamoxifen response in breast cancer patients
  • Discovered SOX11 to be a novel histological marker for mantle cell lymphoma forming the basis for an improved clinical diagnosis
  • Identified SOX11 as a potential tumor suppressor gene in mantle cell lymphoma and ovarian cancer
  • Designed a novel serum-based clinical test for ovarian cancer, which makes it possible to distinguish between benign, malignant and 'borderline' cases 
  • Identified HIF-2a as a therapeutic target for tumor stem cells of neurally derived tumors
  • Discovered serum biomarker signatures that identify pancreatic cancer, forming the basis for an early diagnostic test
  • Identified gene expression subtypes with correlation to prognosis in stage IV malignant melanoma
  • Developed a method to monitor the state of DNA repair pathways, which opens up for defining targets for therapeutic interventions
  • Developed a high-throughput and sensitive protein affinity extraction platform, which directly interfaces with MALDI. This offers new means for rapid screening of biomarkers in complex biofluids.
Page Manager:

MAD for Cancer

A program managed by CREATE Health


Information material